News
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
Pfizer Inc. (NYSE: PFE) today announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study to evaluate the investigational novel
Dr. Mikael Dolsten Named to Agilent Board of Directors
Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to
Humana and Kelsey-Seybold Clinic Team up to Expand Access to Value-based Care, Broadening Humana’s Medicare Advantage Provider Network in the Greater Houston Area
Humana, a leading health and well-being company, and Kelsey-Seybold Clinic have signed an in-network agreement, expanding access to care to include members of Humana Medicare Advantage HMO plans.
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 2, 2021. The
Pfizer Declares Fourth-Quarter 2021 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent fourth-quarter 2021 dividend on the company’s common stock, payable December 6, 2021, to holders of the Common
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech
Agilent Announces Cash Dividend of 19.4 Cents per Share
Agilent Technologies, Inc. (NYSE: A) today announced that a quarterly dividend of 19.4 cents per share of common stock will be paid on Oct. 27, 2021, to all shareholders of record as of the close
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the Cantor Global Healthcare Conference on Monday
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted
Waters BioAccord System with ACQUITY Premier Brings Greater Simplicity, Accuracy and Reproducibility to Multi-Attribute Monitoring of Biopharmaceuticals
Waters Corporation (NYSE:WAT) today introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with
Humana Expands Upon Its Bold Goal Initiative with $25 Million Affordable Housing Investment
As part of its population health strategy to improve the health of its members and communities, Humana Inc. (NYSE: HUM) today announced a $25 million investment to increase the supply of affordable
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO® (abrocitinib), an oral
Curant Health and Humana Launch Pilot Program to Address Medication Adherence and Enhance Patient Care for Members with Complex Health Needs
Curant Health and Humana Inc. (NYSE: HUM) have teamed up to help achieve better health outcomes for Humana members suffering from Chronic Heart Failure (CHF) and Chronic Obstructive Pulmonary
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences.
Frank D’Amelio, Chief
Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute
Agilent Technologies Inc. (NYSE: A) today announced Dr. David R. Liu has been selected to receive a prestigious Agilent Thought Leader Award. A prominent researcher in the field of genome editing
Humana Foundation Donates $500,000 to Support Disaster Recovery in the Wake of Hurricane Ida
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $500,000 towards relief and recovery efforts for those impacted by Hurricane Ida in Louisiana
Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement
Agilent Technologies Inc. (NYSE: A) today announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease), a Phase 3 clinical trial evaluating the efficacy
Agilent to Present at Wells Fargo Virtual Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, Agilent President and CEO, and Bob McMahon, Agilent CFO, will participate in a “fireside chat” discussion at the Wells Fargo
Humana Foundation Donates $50,000 in Relief Efforts for Those Impacted by Flooding in Tennessee
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $50,000 in relief efforts for those impacted by recent flooding across Tennessee. This giving
Texas A&M University Mays Business School and Humana to Launch Fifth Annual Healthcare Analytics Case Competition
Mays Business School at Texas A&M University and leading health and well-being company Humana Inc. (NYSE: HUM) have announced the details of the 2021 Humana-Mays Healthcare Analytics Case